Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 28007457

Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer (CLIN1001 PCM301): an open-label, phase 3, randomised controlled trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet Oncol
Publication date
2017 Feb
First author
Azzouzi AR

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2017 Feb;18(2):156-157. doi: 10.1016/S1470-2045(16)30651-9.
    note
    Source null
    related pmid
    28007456
    relationship
    Comment in
  2. citation
    Nat Rev Urol. 2017 Mar;14(3):134. doi: 10.1038/nrurol.2017.1.
    note
    Source null
    related pmid
    28072400
    relationship
    Comment in
  3. citation
    Lancet Oncol. 2017 Apr;18(4):e187. doi: 10.1016/S1470-2045(17)30170-5.
    note
    Source null
    related pmid
    28368249
    relationship
    Comment in
  4. citation
    Lancet Oncol. 2017 Apr;18(4):e188. doi: 10.1016/S1470-2045(17)30163-8.
    note
    Source null
    related pmid
    28368250
    relationship
    Comment in
  5. citation
    J Urol. 2017 Aug;198(2):255-257. doi: 10.1016/j.juro.2017.05.029.
    note
    Source null
    related pmid
    29370650
    relationship
    Comment in

Authors and identifiers

  1. name
    Azzouzi AR
    type
    Author
  2. name
    Vincendeau S
    type
    Author
  3. name
    Barret E
    type
    Author
  4. name
    Cicco A
    type
    Author
  5. name
    Kleinclauss F
    type
    Author
  6. name
    van der Poel HG
    type
    Author
  7. name
    Stief CG
    type
    Author
  8. name
    Rassweiler J
    type
    Author
  9. name
    Salomon G
    type
    Author
  10. name
    Solsona E
    type
    Author
  11. name
    Alcaraz A
    type
    Author
  12. name
    Tammela TT
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Azzouzi AR
    type
    Author
  2. name
    Vincendeau S
    type
    Author
  3. name
    Barret E
    type
    Author
  4. name
    Cicco A
    type
    Author
  5. name
    Kleinclauss F
    type
    Author
  6. name
    van der Poel HG
    type
    Author
  7. name
    Stief CG
    type
    Author
  8. name
    Rassweiler J
    type
    Author
  9. name
    Salomon G
    type
    Author
  10. name
    Solsona E
    type
    Author
  11. name
    Alcaraz A
    type
    Author
  12. name
    Tammela TT
    type
    Author
bibliography ids
  1. nci-bib-3adb4da7d60b83181846d70f
book metadata
content sha256
98231217a4b2c8e213b678e6b061327e821c9d2960ea405816289a2ae36939c9
document type
citation
dois
  1. 10.1016/S1470-2045(16)30661-1
electronic publication date
display
2016 Dec 20
precision
day
year
2016
evidence scope
bibliographic_metadata_only
id
pubmed:28007457
immutable id
pubmed:28007457@98231217a4b2c8e213b678e6b061327e821c9d2960ea405816289a2ae36939c9
journal
abbreviation
Lancet Oncol
issn electronic
1474-5488
issn print
1470-2045
issue
2
name
The Lancet. Oncology
nlm unique id
100957246
pages
181-191
volume
18
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2017 Feb;18(2):156-157. doi: 10.1016/S1470-2045(16)30651-9.
    note
    Source null
    related pmid
    28007456
    relationship
    Comment in
  2. citation
    Nat Rev Urol. 2017 Mar;14(3):134. doi: 10.1038/nrurol.2017.1.
    note
    Source null
    related pmid
    28072400
    relationship
    Comment in
  3. citation
    Lancet Oncol. 2017 Apr;18(4):e187. doi: 10.1016/S1470-2045(17)30170-5.
    note
    Source null
    related pmid
    28368249
    relationship
    Comment in
  4. citation
    Lancet Oncol. 2017 Apr;18(4):e188. doi: 10.1016/S1470-2045(17)30163-8.
    note
    Source null
    related pmid
    28368250
    relationship
    Comment in
  5. citation
    J Urol. 2017 Aug;198(2):255-257. doi: 10.1016/j.juro.2017.05.029.
    note
    Source null
    related pmid
    29370650
    relationship
    Comment in
outcomes validated
false
pmid
28007457
provenance
batch id
7a1288ac8bb5f9826304
provider
NCBI PubMed ESummary
record sha256
32128d5a08f15d7acb7354b8d7ee59302196800bfc0898db3035716982417a12
response sha256
0e879bec8c19d1cfda5629dca8745b04155d18cf54361825d4c070aebad2984d
retrieved at
2026-09-09T23:47:23.138359+00:00
publication date
display
2017 Feb
precision
month
year
2017
publication types
  1. Clinical Trial, Phase III
  2. Comparative Study
  3. Journal Article
  4. Multicenter Study
  5. Randomized Controlled Trial
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/28007457/
title
Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer (CLIN1001 PCM301): an open-label, phase 3, randomised controlled trial.

Preserved source evidence · Not medical advice